Economy/Home · Economy

Celltrion's Zymfentra Receives MFDS Approval for Global Phase 3 Rheumatoid Arthritis Trial... To Involve 296 Patients Over 52 Weeks

Celltrion announced in a regulatory filing on the 14th that it has received approval from the Ministry of Food and Drug Safety (MFDS) for a global Phase 3 clinical trial plan for CT-P13 SC (Zymfentra) for the treatment of rheumatoid arthritis. The trial aims to evaluate the efficacy and safety of th

Oseong Kwon
Staff Reporter
4 min read
Celltrion's Zymfentra Receives MFDS Approval for Global Phase 3 Rheumatoid Arthritis Trial... To Involve 296 Patients Over 52 Weeks
CBC News

Celltrion announced in a regulatory filing on the 14th that it has received approval from the Ministry of Food and Drug Safety (MFDS) for a global Phase 3 clinical trial plan for CT-P13 SC (Zymfentra) for the treatment of rheumatoid arthritis. The trial aims to evaluate the efficacy and safety of the subcutaneous formulation of CT-P13 in patients with moderate to severe active rheumatoid arthritis.

296 Patients Over 52 Weeks... Goal Is to Demonstrate 'Superiority in ACR50 at Week 12'

Celltrion submitted the clinical trial plan on July 24 and confirmed approval on October 14. The trial will involve a total of 296 participants with a 52-week treatment period. It is a global Phase 3 clinical trial conducted as a randomized, placebo-controlled, double-blind, parallel-group study.

The primary objective of the trial is to demonstrate that CT-P13 SC is superior to placebo in terms of efficacy by evaluating clinical response based on ACR50, a criterion of the American College of Rheumatology, at week 12 of treatment.

Subcutaneous Form of Remsima IV... Already Approved for Ulcerative Colitis and Crohn's Disease in the US, EU, and Elsewhere

CT-P13 SC (Zymfentra) is a subcutaneous formulation of Remsima IV, a biosimilar of infliximab. Celltrion explained that it developed the product to improve dosing convenience for patients and provide more treatment opportunities.

According to Celltrion, CT-P13 SC has completed Phase 3 trials in adult patients with ulcerative colitis and Crohn's disease, and has obtained product approval in multiple countries including the United States and Europe. The company stated that through this Phase 3 rheumatoid arthritis trial, it expects to provide treatment opportunities to more patients in addition to its existing indications.

'Statistical Probability of Clinical Success Is About 10%... Commercialization Plans May Change'

Meanwhile, Celltrion disclosed through an investor notice that the statistical probability of an investigational drug receiving final drug approval is known to be around 10%, and that if results during the clinical trial or product approval process fall short of expectations, it may change or abandon its commercialization plans.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.